tm2624918-2_424b5 - none

424B5 1 tm2624918-2_424b5.htm 424B5 tm2624918-2_424b5 - none - 4.3952349s

Filed pursuant to Rule 424(b)(5)

Registration No. 333-277609

PROSPECTUS SUPPLEMENT
(To Prospectus Dated August 19, 2026)

[MISSING IMAGE: lg_yarrowbioscience-4c.jpg]

5,769,231 Shares of Common Stock

We are offering 5,769,231 shares of our common stock. The public offering price for each share of common stock is $26.00. Our common stock trades on the Nasdaq Capital Market (“Nasdaq”) under the symbol “YARW.” On September 9, 2026, the last reported sale price for our common stock on Nasdaq was $29.11 per share.

Investing in our common stock involves risks. See the section titled “Risk Factors” beginning on page S-6 of this prospectus supplement and page 4 of the accompanying prospectus, as well as in the documents incorporated by reference herein and therein, to read about factors you should consider before buying shares of our common stock.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved these securities, or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

	PER SHARE			TOTAL
Public Offering Price		$	26.00		$	150,000,006.00
Underwriting Discounts and Commissions(1)		$	1.56		$	9,000,000.36
Proceeds, Before Expenses, to Yarrow Bioscience, Inc.		$	24.44		$	141,000,005.64

(1)

See the section titled “Underwriting” for additional information regarding underwriting compensation.

Delivery of the shares of common stock is expected to be made on or about September 14, 2026.

We have granted the underwriters an option for a period of 30 days to purchase up to an additional 865,384 shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $10,349,999.40 and the total proceeds to us, before expenses, will be $162,149,990.60.

Joint Book-Running Managers

Jefferies

TD Cowen

Guggenheim Securities

Lead Manager

LifeSci Capital

Prospectus supplement, dated September 10, 2026

	Page
ABOUT THIS PROSPECTUS SUPPLEMENT		S-1
PROSPECTUS SUPPLEMENT SUMMARY		S-2
THE OFFERING		S-4
RISK FACTORS		S-6
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		S-8
USE OF PROCEEDS		S-10
UNDERWRITING		S-11
LEGAL MATTERS		S-20
EXPERTS		S-21
WHERE YOU CAN FIND MORE INFORMATION		S-22
INCORPORATION BY REFERENCE		S-23

	Page
ABOUT THIS PROSPECTUS		ii
SUMMARY		1
RISK FACTORS		4
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		5
USE OF PROCEEDS		7
SECURITIES WE MAY OFFER		8
PLAN OF DISTRIBUTION		14
LEGAL MATTERS		17
EXPERTS		17
WHERE YOU CAN FIND MORE INFORMATION		18
INCORPORATION BY REFERENCE		19

UNDERWRITER	NUMBER OF SHARES
Jefferies LLC		2,163,462
TD Securities (USA) LLC		1,730,770
Guggenheim Securities, LLC		1,153,846
LifeSci Capital LLC		721,153
Total		5,769,231

	Per Share			Total Without Option to Purchase Additional Shares			Total With Option to Purchase Additional Shares
Public offering price		$	26.00		$	150,000,006.00		$	172,499,990.00
Underwriting discounts and commissions paid by us		$	1.56		$	9,000,000.36		$	10,349,999.40
Proceeds to us, before expenses		$	24.44		$	141,000,005.64		$	162,149,990.60